Halozyme Therapeutics' (HALO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $50.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the stock. TD Cowen began coverage on shares of […]

Related Keywords

Boston ,Massachusetts ,United States ,Belgium ,Japan ,Switzerland ,Michaelj Labarre , ,Halozyme Therapeutics Company Profile ,Wafra Inc ,Hsbc Holdings ,Nasdaq ,International Assets Investment Management ,Halozyme Therapeutics Inc ,Harvey Capital Management Inc ,Halozyme Therapeutics ,Free Report ,Moderate Buy ,Therapeutics Stock Down ,Assets Investment Management ,Capital Management ,Get Free Report ,Halozyme Therapeutics Daily ,